Albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The WAV, run by the Ministry of Defence, recruited and trained female personnel for the WAAS and the WAMS, which respectively came under the Air and Defence Ministries. According to the official statement announcing their formation, the services' purpose was "to substitute women for men wherever necessary and practicable throughout the military and air forces within Southern Rhodesia." Recruitment for the women's services began in June 1941. Most volunteers were married women, many of them the wives of military men. The air and military services both offered a wide variety of positions. In addition to jobs as typists, clerks, caterers and the like, women served as drivers and in the stores and workshops. Many of the women in the air service did skilled work, checking flying instruments, testing parts and doing minor repairs. The women of the Auxiliary Police Service served as BSAP officers both in stations and on the streets. Members of Southern Rhodesia's white female population who did not join the forces still contributed to the war in various ways. Women worked in munitions factories and engineering workshops in Salisbury and Bulawayo. The Women's National Service League, which thousands of women joined before the war even started, revived the role white Rhodesian women had played in World War I, sending the colony's servicemen overseas parcels containing warm clothes, newspapers, razor blades, soap, food and minor luxuries such as sweets, tobacco and novels. Efforts such as these did much to keep the troops' morale up.
The unit of account of the bitcoin system is the bitcoin. It is most commonly represented with the symbol ₿ designed in 2010 and the currency code BTC. However, the BTC code does not conform to ISO 4217 as BT is the country code of Bhutan, and ISO 4217 requires the first letter used in global commodities to be 'X'. XBT, a code that conforms to ISO 4217 though not officially part of it, is used by Bloomberg L.P. No uniform capitalization convention exists; some sources use Bitcoin, capitalized, to refer to the technology and network, and bitcoin, lowercase, for the unit of account. The Cambridge Advanced Learner's Dictionary and the Oxford Advanced Learner's Dictionary use the capitalized and lowercase variants without distinction. One bitcoin is divisible to eight decimal places. Units for smaller amounts of bitcoin are the millibitcoin (mBTC), equal to 1⁄1000 bitcoin, and the satoshi (sat), representing 1⁄100000000 (one hundred millionth) bitcoin, the smallest amount possible. 100,000 satoshis are one mBTC.
In 2012, the Center for Blood Research, which had changed its name to the Immune Disease Institute, merged with Boston Children's Hospital and became the Program in Cellular and Molecular Medicine of Boston Children's Hospital.
Sources: en.wikipedia.org
While Navi Pillay, the UN High Commissioner for Human Rights, said that both sides in the conflict appeared to have committed war crimes in 2012, United Nations' Independent International Commission of Inquiry on Syria also blamed the vast majority of atrocities on the Assad government forces. Baathist forces were responsible for vast majority of the killings during the war, far outstripping casualties inflicted by groups like IS. Over 21,000 deaths occurred in 2015 alone, with more than 75% of them (over 15,700) being perpetrated by Syrian regime forces. Regime attacks also resulted in more than 12,000 civilian deaths, with around 38% of the victims being women and children. On 2 March 2018, UN High Commissioner for Human Rights, Zeid Ra'ad Al Hussein said, "Syria must be referred to the International Criminal Court. Attempts to thwart justice, and shield these criminals, are disgraceful." Commission for International Justice and Accountability (CIJA), an independent war-crimes documentation agency has been conducting investigations on the crimes and atrocities committed during the Syrian war, with the organization employing around a hundred Syrians and Iraqis in the country, some of them insiders within the state bureaucratic apparatus.
== History == Identification of the Rho family of GTPases began in the mid-1980s. The first identified Rho member was RhoA, isolated serendipitously in 1985 from a low stringency cDNA screening. Rac1 and Rac2 were identified next, in 1989 followed by Cdc42 in 1990. Eight additional mammalian Rho members were identified from biological screenings until the late 1990s, a turning point in biology where availability of complete genome sequences allowed full identification of gene families. All eukaryote cells contain Rho GTPase (ranging from 6 in yeast to 20 in mammals). In mammals, the Rho family is thus made of 20 members distributed in 8 subfamilies: Rho, Rnd, RhoD/F, RhoH, Rac, Cdc42, RhoU/V and RhoBTB. As early as 1990, Paterson et al. began expressing activated Rho protein in Swiss 3T3 fibroblasts. By the mid-1990s, Rho proteins had been observed to affect the formation of cellular projections ("processes") in fibroblasts. In a 1998 review article, Alan Hall compiled evidence showing that not only do fibroblasts form processes upon Rho activation, but so do virtually all eukaryotic cells. A 2006 review article by Bement et al. explored the significance of spatial zones of Rho activation.
=== Zebrafish === Upon injury, zebrafish (Danio rerio) cardiomyocytes have been found to have the capability to differentiate and subsequently rapidly proliferate as a wound healing response. Specifically, resection of up to 20% of the zebrafish ventricle regenerates via the proliferation of already differentiated cardiomyocyte. The cardiomyocytes dedifferentiation is observed through detachment from other cells as well as changes in morphology.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.